Literature DB >> 12933524

Linear regression analysis of censored medical costs.

D Y Lin1.   

Abstract

This paper deals with the problem of linear regression for medical cost data when some study subjects are not followed for the full duration of interest so that their total costs are unknown. Standard survival analysis techniques are ill-suited to this type of censoring. The familiar normal equations for the least-squares estimation are modified in several ways to properly account for the incompleteness of the data. The resulting estimators are shown to be consistent and asymptotically normal with easily estimated variance-covariance matrices. The proposed methodology can be used when the cost database contains only the total costs for those with complete follow-up. More efficient estimators are available when the cost data are recorded in multiple time intervals. A study on the medical cost for ovarian cancer is presented.

Entities:  

Year:  2000        PMID: 12933524     DOI: 10.1093/biostatistics/1.1.35

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  56 in total

1.  Medical costs of abnormal serum sodium levels.

Authors:  Alisa M Shea; Bradley G Hammill; Lesley H Curtis; Lynda A Szczech; Kevin A Schulman
Journal:  J Am Soc Nephrol       Date:  2008-01-23       Impact factor: 10.121

2.  Economic evaluation of pemetrexed versus erlotinib as second-line treatment of patients with advanced/metastatic non-small cell lung cancer in Greece: a cost minimization analysis.

Authors:  V F Fragoulakis; A G Pallis; D K Kaitelidou; N M Maniadakis; V G Georgoulias
Journal:  Lung Cancer (Auckl)       Date:  2012-07-16

3.  Health economic burden of patients with restless legs syndrome in a German ambulatory setting.

Authors:  Richard Dodel; Svenja Happe; Ines Peglau; Geert Mayer; Jürgen Wasem; Jens-Peter Reese; Guido Giani; Max Geraedts; Claudia Trenkwalder; Wolfgang H Oertel; Karin Stiasny-Kolster
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

4.  Cost-effectiveness of extended buprenorphine-naloxone treatment for opioid-dependent youth: data from a randomized trial.

Authors:  Daniel Polsky; Henry A Glick; Jianing Yang; Geetha A Subramaniam; Sabrina A Poole; George E Woody
Journal:  Addiction       Date:  2010-07-12       Impact factor: 6.526

5.  Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma.

Authors:  Christopher S Hollenbeak; Lucas E Nikkel; Eric W Schaefer; Evo Alemao; Nasrollah Ghahramani; Jay D Raman
Journal:  J Manag Care Pharm       Date:  2011-10

6.  EVALUATING COSTS WITH UNMEASURED CONFOUNDING: A SENSITIVITY ANALYSIS FOR THE TREATMENT EFFECT.

Authors:  Elizabeth A Handorf; Justin E Bekelman; Daniel F Heitjan; Nandita Mitra
Journal:  Ann Appl Stat       Date:  2013       Impact factor: 2.083

7.  Economic impact and long-term graft outcomes of mycophenolate mofetil dosage modifications following gastrointestinal complications in renal transplant recipients.

Authors:  Gerardo Machnicki; Jean-Francois Ricci; Daniel C Brennan; Mark A Schnitzler
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

8.  Comparative and cost effectiveness of treatment modalities for hepatocellular carcinoma in SEER-Medicare.

Authors:  Fadia T Shaya; Ian M Breunig; Brian Seal; C Daniel Mullins; Viktor V Chirikov; Nader Hanna
Journal:  Pharmacoeconomics       Date:  2014-01       Impact factor: 4.981

9.  A joint latent class analysis for adjusting survival bias with application to a trauma transfusion study.

Authors:  Jing Ning; Mohammad H Rahbar; Sangbum Choi; Chuan Hong; Jin Piao; Deborah J del Junco; Erin E Fox; Elaheh Rahbar; John B Holcomb
Journal:  Stat Med       Date:  2015-08-09       Impact factor: 2.373

10.  Cost effectiveness analysis of larval therapy for leg ulcers.

Authors:  Marta O Soares; Cynthia P Iglesias; J Martin Bland; Nicky Cullum; Jo C Dumville; E Andrea Nelson; David J Torgerson; Gill Worthy
Journal:  BMJ       Date:  2009-03-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.